gefitinib has been researched along with n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) | Trials (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) | Recent Studies (post-2010) (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,220 | 3 | 229 |
| Protein | Taxonomy | gefitinib (IC50) | n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide (IC50) |
|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | 10 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 2.1 | |
| Aromatase | Homo sapiens (human) | 0.68 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 1.67 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.9037 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4333 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.1522 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 1.8 | |
| Prostaglandin E synthase | Mus musculus (house mouse) | 0.007 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigues, S; Thim, L; Van Aken, E; Van Bocxlaer, S; Westley, BR | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
2 other study(ies) available for gefitinib and n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
| Article | Year |
|---|---|
Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling.
Topics: Allantois; Angiogenesis Inducing Agents; Animals; Capillaries; Cells, Cultured; Chick Embryo; Chorion; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Growth Substances; Humans; Isoenzymes; Membrane Proteins; Morphogenesis; Mucins; Muscle Proteins; Neovascularization, Physiologic; Neuropeptides; Nitrobenzenes; Peptides; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Sulfonamides; Trefoil Factor-2; Trefoil Factor-3 | 2003 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |